<DOC>
	<DOCNO>NCT01457677</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo-controlled , parallel-group study investigate efficacy safety RO4995819 adjunctive therapy patient major depressive disorder inadequate response ongoing antidepressant treatment . Patients randomize receive daily dose 5 mg , 15 30 mg RO4995819 match placebo . The anticipated time study treatment 6 week .</brief_summary>
	<brief_title>ARTDeCo Study : A Study RO4995819 Patients With Major Depressive Disorder And Inadequate Response Ongoing Antidepressant Treatment</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Adult patient , 1865 year age Major depression disorder without psychotic feature Inadequate response current , ongoing antidepressant treatment define protocol Having least one 2 antidepressant treatment trial failure Body mass index ( BMI ) 18.035.0 kg/m2 inclusive Patient currently receive treatment combination 3 antidepressant Significant ongoing use high dos barbiturate , benzodiazepine anxiolytic drug Patient previously receive RO4995819 Patient participate investigational drug device trial within 6 month screen History nonresponse , current use nonpharmacological treatment include Electroconvulsive Therapy ( ECT ) , Vagus Nerve Stimulation ( VNS ) , Repetitive Transcranial Magnetic Stimulation ( RTMS ) Past present psychotic symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>